Form 4: Supernus Pharmaceuticals CEO Jack A. Khattar Executes Stock Option and Sells Shares

Jack A. Khattar, CEO of Supernus Pharmaceuticals, exercised stock options and sold 125,000 shares of common stock on November 8, 2024.

Summary

• On November 8, 2024, Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, exercised employee stock options to acquire 125,000 shares of common stock at a price of $9.13 per share.
• Simultaneously, Khattar sold 125,000 shares of Supernus common stock at a weighted average price of $36.29, with individual sales prices ranging from $35.87 to $36.66.
• Following these transactions, Khattar directly owns 926,172 shares of Supernus common stock and indirectly owns 1,022,450 shares through the KBT Trust.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of insider trading activity and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives to exercise stock options and sell shares for personal financial management.

Comparison to Industry Standards

• Executive compensation packages often include stock options as incentives.
• The exercise and sale of shares by executives are common and are typically disclosed through SEC filings like Form 4.
• The reported transactions are within the normal range of executive stock option exercises and sales.

Stakeholder Impact

• The transaction could have a minor impact on shareholders due to the change in ownership.
• The sale of shares by the CEO could be perceived as a lack of confidence in the company, although it is a common practice for executives to diversify their assets.

Key Dates